{"filings":[{"id":110143,"accession_number":"0001493152-26-008994","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ZyVersa raises $1M via convertible notes and warrants for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1M aggregate principal 10% convertible promissory notes, maturing in 12 months, with a $0.02 floor price on conversion.","Notes convertible at 80% of the lowest daily VWAP during the 10 trading days prior to conversion notice.","Series A-4 warrants exercisable six months post-issuance, expiring in 5 years; exercise price linked to qualified offering or VWAP.","Proceeds to be used for working capital; obligations guaranteed by subsidiary ZyVersa Therapeutics Operating, Inc.","Securities sold to accredited investors in a private placement under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126688,"accession_number":"0001493152-25-025966","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZyVersa director Robert Finizio resigns from board effective Dec 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Independent director Robert G. Finizio resigned as board member, Compensation Committee chair, and Audit Committee member.","Resignation effective immediately on December 2, 2025; accepted by the Board.","Resignation was for personal reasons, not due to any disagreement with the Company on operations, policies, or practices.","No replacement has been announced for the vacated board or committee positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126687,"accession_number":"0001493152-25-024273","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.","Net loss $19.8M vs $2.4M in Q3 2024, driven by $18.6M impairment of in-process R&D due to market cap decline.","Pre-tax loss $20.7M; R&D expense $0.4M (-16.3% YoY), G&A $1.7M (-5.1% YoY).","Raised $2.05M in Q3 2025, $4.05M YTD; company flags need for equity/debt or collaboration funding.","Lead programs: VAR 200 for FSGS (kidney) and IC 100 for cardiometabolic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126686,"accession_number":"0001493152-25-018156","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZyVersa CMO Pablo Guzman resigns Oct 10, 2025 to focus on family","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pablo Guzman, M.D., resigned as CMO and SVP of Medical Affairs, effective October 10, 2025.","Dr. Guzman joined ZyVersa in January 2015 with over 35 years of medical experience.","Resignation reason: personal (spend time with family and travel); no replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143470,"accession_number":"0001493152-25-013968","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq to delist ZyVersa Therapeutics common stock effective ~Sep 28, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ZyVersa on Sept 14, 2025, of delisting; Form 25 to be filed on or about Sept 18, 2025.","Stock was suspended from Nasdaq on July 17, 2025; trading on OTCQB since July 28, 2025 under symbol ZVSA.","Delisting effective ten days after Form 25 filing; company cites failure to meet minimum bid price rule.","Company's common stock will continue trading on OTCQB without disruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143469,"accession_number":"0001641172-25-021100","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics common stock to trade on OTCQB from July 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OTCQB approval received on July 25, 2025; trading commences July 28 under ticker ZVSA.","Move to OTCQB indicates likely delisting from a senior exchange (e.g., Nasdaq).","No financial terms disclosed; company remains an SEC filer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143468,"accession_number":"0001641172-25-019856","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics receives Nasdaq delisting notice; trading suspended July 17","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel denied request to continue listing on the Nasdaq Capital Market.","Common stock trading suspended at open on July 17, 2025; plans to trade on OTC Pink Limited Market.","Delisting stems from non-compliance with minimum bid price requirement under Rule 5550(a)(2).","Company may request review by Nasdaq Council within 15 days of Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143467,"accession_number":"0001641172-25-018403","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.","Company issues new Series A-4 warrants to purchase 200% of exercised shares, $0.67 exercise price, 5-year term.","If all warrants exercised, gross proceeds ~$2.05 million; proceeds for working capital.","Issuance of inducement warrant shares subject to stockholder approval; registration statement to be filed by August 8, 2025.","AGP acts as financial advisor, receiving 6.5% cash fee of aggregate gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161662,"accession_number":"0001641172-25-016388","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ZyVersa enters $10M equity purchase agreement with Williamsburg Venture Holdings to fund VAR 200 clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $10M of common stock; company controls timing and amount of sales over 24-month term.","Purchase price set at 94% of lowest VWAP during three trading days after each sale clears.","2.5% commitment fee in common shares, with piggyback registration rights; no warrants or derivatives.","Funds intended to progress clinical development of Cholesterol Efflux Mediator TM VAR 200 for chronic kidney disease.","Issuance capped at 19.99% of outstanding shares unless stockholder approval is obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161661,"accession_number":"0001641172-25-014895","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ZyVersa shareholders approve up to 3.84M new shares, potentially doubling float","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing equity plan share reserve by 100,000 to 382,122 shares.","Approved issuance of up to 1,637,000 shares upon exercise of November 2024 warrants.","Approved issuance of up to 2,105,265 shares upon exercise of March 2025 warrants.","Combined potential dilution (3.84M shares) exceeds current outstanding of 3.62M shares.","All five proposals including director re-election and auditor ratification passed at June 11 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161660,"accession_number":"0001641172-25-013038","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Zyversa receives Nasdaq delisting notice for low bid price; will appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.","Ineligible for cure period due to two reverse stock splits in past two years (1:35 Dec 2023, 1:10 Apr 2024).","Unless appeal requested by June 3, 2025, securities face delisting on June 5, 2025.","Company intends to appeal and request hearing, which will stay delisting pending panel decision.","No assurance of regaining compliance with continued listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161659,"accession_number":"0001641172-25-003034","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ZyVersa Therapeutics replaces auditor Marcum LLP with CBIZ CPAs; notes material weaknesses and going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.","Marcum's reports for FY2023 and FY2024 included an explanatory paragraph about substantial doubt on the company's ability to continue as a going concern.","Company disclosed material weaknesses in internal control over financial reporting for both FY2023 and FY2024, including lack of segregation of duties.","No disagreements on accounting principles occurred between the company and Marcum during the relevant periods.","Marcum furnished a letter agreeing with the statements; filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179770,"accession_number":"0001493152-25-009571","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","3.02","5.07","8.01","5.08","9.01"],"status":"ready","headline":"ZyVersa raises ~$2M in private placement; special meeting adjourned without quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2M from private placement of pre-funded and common warrants; pre-funded warrants priced at $0.9499.","Common warrants exercisable at $1.00/share, expire 5 years after stockholder approval.","Existing warrants from Nov 2024 amended to reduce exercise price to $1.00 per share.","Special meeting on Mar 4 lacked quorum; proposals move to 2025 annual meeting set for June 11, 2025.","Record date for 2025 annual meeting is April 15, 2025; stockholder proposals due by March 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196537,"accession_number":"0001493152-24-045371","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.","Cash at Sept 30, 2024: $0.1M; company will need additional financing on a month-to-month basis.","Phase 2a trial for VAR 200 in diabetic kidney disease expected to begin Q1 2025 with data mid-2025.","IC 100 IND submission planned for Q2 2025; Phase 1 trial in overweight subjects planned Q2/Q3 2025.","Raised ~$3.9M from Q3 2024 to present; formed new Obesity, Metabolic & Inflammatory Disease SAB."],"consensus_eps_estimate":-3.774,"consensus_eps_actual":-9.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196536,"accession_number":"0001493152-24-043754","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa raises ~$1.7M via warrant exercise inducement at $2.06/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holders exercise at reduced price of $2.06/share; gross proceeds ~$1.7M.","Company issues new Series A-2 warrants for 200% of exercised shares, exercise price $2.06, 5-year term.","Engaged A.G.P./Alliance Global Partners as financial advisor; cash fee $110,000 plus $10k expenses.","Net proceeds for working capital and general corporate purposes.","Company to file resale registration statement for new warrant shares by Dec 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196535,"accession_number":"0001493152-24-043066","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.","Ratified Marcum LLP as independent auditor for FY2024 with 433,670 votes for.","Approved amendment to 2022 Omnibus Equity Incentive Plan, increasing shares reserved by 150,000 to 181,795.","Approved issuance of up to 478,600 shares upon exercise of certain warrants under Nasdaq Listing Rule 5635(d).","Quorum of approx. 43% of outstanding shares (1,074,196 shares) was represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212839,"accession_number":"0001493152-24-036453","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["1.0","9.01"],"status":"ready","headline":"Zyversa Therapeutics enters $1.4M ATM equity offering with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Agreement with A.G.P./Alliance Global Partners to sell up to $1,397,396 of common stock.","Agent receives 3.0% commission; sales at prevailing market prices under effective shelf registration.","Proceeds to be used for working capital and general corporate purposes, including R&D.","No minimum offering; Company not obligated to sell any shares under the Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212838,"accession_number":"0001493152-24-029868","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZyVersa raises ~$830k via warrant inducement at $3.46; issues 200% new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercises existing Series A/B warrants at reduced price $3.46 (from $12.50), gross proceeds ~$830k.","New Series A-1 warrants for 392k shares (5-yr term) and Series B-1 for 86.6k shares (18-mo term), all at $3.46.","New warrant shares subject to stockholder approval; meeting to be held within 90 days of closing.","Engaged A.G.P./Alliance Global Partners as financial advisor for $50k cash fee.","Company to file resale registration statement for new warrant shares by September 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231895,"accession_number":"0001493152-24-015938","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"ZyVersa Therapeutics executes 1-for-10 reverse stock split effective April 25, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-10; approved by stockholders at special meeting on April 17, 2024.","Effective at 4:01 p.m. ET on April 25; split-adjusted trading begins April 26 on Nasdaq.","Par value unchanged; new CUSIP number is 98987D 300.","Common stock continues trading under symbol ZVSA on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231894,"accession_number":"0001493152-24-015041","cik":1859007,"company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["5.07","7.01"],"status":"ready","headline":"ZyVersa shareholders approve reverse stock split; board sets 1-for-10 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split at special meeting on April 17, 2024, with 2,058,182 votes for and 899,831 against.","Board of directors subsequently authorized a 1-for-10 reverse stock split ratio.","Reverse stock split effective at 4:01 p.m. ET on April 25, 2024; post-split trading begins April 26, 2024.","New CUSIP number for common stock after reverse split: 98987D 300."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1500000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}